ASX:MSBBiotechs
Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?
Why this FDA milestone matters for Mesoblast
Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks.
This regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...